Galera Therapeutics is a biopharmaceutical company based in St. Louis, Missouri, specializing in the development of treatments to mitigate the harmful effects of radiation therapy. Led by Dr. J. Mel Sorensen, the company has raised $60 million through an initial public offering and is focused on advancing its lead drug candidate, GC4419, for the treatment of severe oral mucositis in patients with head and neck cancer.
With a team of 26 employees, Galera operates locally at the Helix Center in the 39 North innovation district and has received support from St. Louis investors such as the St. Louis Arch Angels, BioGenerator, and Cultivation Capital. The company's IPO follows a successful Series C financing round of $150 million, making it one of the largest funding rounds for a bioscience company in St. Louis. Galera's mission is to improve the quality of life for cancer patients undergoing radiation therapy through innovative drug development.
Generated from the website